Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Howard M Katzenstein
Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531
CONFLICT OF INTEREST STATEMENT As of April 2023, Howard M. Katzenstein is employed at Merck and Co. Inc., Rahway NJ; all study conduct was prior to his employment. Arlene Naranjo serves on a data safety monitoring committee for Novartis. Supporting Information Filename Description pbc31407-sup-0001-TableS1.docx32.2 KB Supporting Information REFERENCES 1, . Advancing therapy for neuroblastoma. Nat Rev Clin Oncol. 2022; 19: 515-533. 2, , , et al.
Children's Oncology Group's 2023 blueprint for research: Liver tumors
AFP alpha-fetoprotein C5V cisplatin/5-FU/vincristine C5VD cisplatin/5-FU/vincristine/doxorubicin CHIC Children's Hepatic tumors International Collaboration COG Children's Oncology Group FLC fibrolamellar carcinoma HB hepatoblastoma HCC hepatocellular carcinoma HCN-NOS hepatocellular neoplasm not otherwise specified OS overall survival PHITT Paediatric Hepatic International Tumour Trial PRETEXT Pretreatment Extent of Disease SIOPEL Société Internationale d'Oncologie Pédiatrique—Epithelial...
Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee | Journal of Clinical Oncology
Abstract Small cell undifferentiated (SCU) histology in hepatoblastoma (HB) tumors has historically been associated with a poor prognosis. Tumors from patients enrolled on Children's Oncology Group (COG) study AHEP0731 underwent institutional and central pathologic review for identification of SCU histology.
Doxorubicin in combination with cisplatin, 5‐flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study
Original Article Howard M. Katzenstein MD, Corresponding Author howchar9@gmail.com orcid.org/0000-0002-5314-2972 Nemours Children's Specialty Care and Wolfson Children's Hospital, Jacksonville, Florida Corresponding Author: Howard M. Katzenstein, MD, 552 Victory Rd, N331, Quincy, MA 02171 (howchar9@gmail.com). Search for more papers by this author Marcio H.
Vaping the Venom: Oral Cavity Cancer in a Young Adult With Extensive Electronic Cigarette Use
Thank you for your interest in spreading the word on American Academy of Pediatrics. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial
Summary Background Hepatoblastoma treatment with curative intent requires surgical resection, but only about a third of newly diagnosed patients with hepatoblastoma have resectable disease at diagnosis. Patients who have upfront resection typically receive a total of 4–6 cycles of adjuvant chemotherapy post-surgery, with the combination of cisplatin, fluorouracil, and vincristine.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Howard M
Contact Howard M, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack